nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—SLC6A3—Gilles de la Tourette syndrome	0.566	0.635	CbGaD
Nefazodone—HTR2A—Gilles de la Tourette syndrome	0.325	0.365	CbGaD
Nefazodone—SLC6A2—autonomic nervous system—Gilles de la Tourette syndrome	0.00623	0.159	CbGeAlD
Nefazodone—HTR2A—autonomic nervous system—Gilles de la Tourette syndrome	0.00375	0.0954	CbGeAlD
Nefazodone—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—Gilles de la Tourette syndrome	0.00156	0.0259	CbGpPWpGaD
Nefazodone—ADRA1B—nervous system—Gilles de la Tourette syndrome	0.0013	0.0332	CbGeAlD
Nefazodone—HTR1A—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.00126	0.0209	CbGpPWpGaD
Nefazodone—ADRA1B—central nervous system—Gilles de la Tourette syndrome	0.00126	0.032	CbGeAlD
Nefazodone—HTR2C—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.00125	0.0208	CbGpPWpGaD
Nefazodone—SLC6A4—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	0.0012	0.0199	CbGpPWpGaD
Nefazodone—SLC6A3—midbrain—Gilles de la Tourette syndrome	0.00119	0.0303	CbGeAlD
Nefazodone—HTR2C—midbrain—Gilles de la Tourette syndrome	0.00115	0.0293	CbGeAlD
Nefazodone—SLC6A4—midbrain—Gilles de la Tourette syndrome	0.00109	0.0277	CbGeAlD
Nefazodone—SLC6A2—Amine compound SLC transporters—SLC6A3—Gilles de la Tourette syndrome	0.00108	0.018	CbGpPWpGaD
Nefazodone—HTR1A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00104	0.0172	CbGpPWpGaD
Nefazodone—HTR2C—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00103	0.0171	CbGpPWpGaD
Nefazodone—SLC6A2—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	0.00103	0.0171	CbGpPWpGaD
Nefazodone—ADRA1B—brain—Gilles de la Tourette syndrome	0.000997	0.0254	CbGeAlD
Nefazodone—ADRA1B—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.000988	0.0164	CbGpPWpGaD
Nefazodone—SLC6A3—nervous system—Gilles de la Tourette syndrome	0.000977	0.0249	CbGeAlD
Nefazodone—HTR1A—midbrain—Gilles de la Tourette syndrome	0.000967	0.0246	CbGeAlD
Nefazodone—HTR2C—nervous system—Gilles de la Tourette syndrome	0.000945	0.0241	CbGeAlD
Nefazodone—SLC6A3—central nervous system—Gilles de la Tourette syndrome	0.000941	0.024	CbGeAlD
Nefazodone—HTR2C—central nervous system—Gilles de la Tourette syndrome	0.000909	0.0232	CbGeAlD
Nefazodone—HTR2A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.000896	0.0149	CbGpPWpGaD
Nefazodone—SLC6A4—nervous system—Gilles de la Tourette syndrome	0.000895	0.0228	CbGeAlD
Nefazodone—HTR1A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000884	0.0147	CbGpPWpGaD
Nefazodone—HTR2C—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00088	0.0146	CbGpPWpGaD
Nefazodone—ADRA1A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.000877	0.0145	CbGpPWpGaD
Nefazodone—SLC6A4—central nervous system—Gilles de la Tourette syndrome	0.000862	0.022	CbGeAlD
Nefazodone—HTR1A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000859	0.0142	CbGpPWpGaD
Nefazodone—HTR2C—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000854	0.0142	CbGpPWpGaD
Nefazodone—ADRA1B—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000842	0.014	CbGpPWpGaD
Nefazodone—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—Gilles de la Tourette syndrome	0.000832	0.0138	CbGpPWpGaD
Nefazodone—ADRA1B—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000818	0.0136	CbGpPWpGaD
Nefazodone—ADRA2A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.000815	0.0135	CbGpPWpGaD
Nefazodone—HTR1A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0008	0.0133	CbGpPWpGaD
Nefazodone—HTR2C—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000796	0.0132	CbGpPWpGaD
Nefazodone—HTR1A—nervous system—Gilles de la Tourette syndrome	0.000795	0.0203	CbGeAlD
Nefazodone—SLC6A2—nervous system—Gilles de la Tourette syndrome	0.000788	0.0201	CbGeAlD
Nefazodone—HTR1A—central nervous system—Gilles de la Tourette syndrome	0.000765	0.0195	CbGeAlD
Nefazodone—HTR2A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000764	0.0127	CbGpPWpGaD
Nefazodone—ADRA1B—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000762	0.0126	CbGpPWpGaD
Nefazodone—SLC6A2—central nervous system—Gilles de la Tourette syndrome	0.000759	0.0193	CbGeAlD
Nefazodone—ADRA1A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000748	0.0124	CbGpPWpGaD
Nefazodone—SLC6A3—brain—Gilles de la Tourette syndrome	0.000747	0.019	CbGeAlD
Nefazodone—HTR1A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000743	0.0123	CbGpPWpGaD
Nefazodone—HTR2A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000742	0.0123	CbGpPWpGaD
Nefazodone—HTR2C—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00074	0.0123	CbGpPWpGaD
Nefazodone—ADRA1A—nervous system—Gilles de la Tourette syndrome	0.000733	0.0187	CbGeAlD
Nefazodone—ADRA1A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000726	0.012	CbGpPWpGaD
Nefazodone—HTR2C—brain—Gilles de la Tourette syndrome	0.000722	0.0184	CbGeAlD
Nefazodone—HTR1A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000722	0.012	CbGpPWpGaD
Nefazodone—HTR2C—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000718	0.0119	CbGpPWpGaD
Nefazodone—ADRA1B—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000708	0.0117	CbGpPWpGaD
Nefazodone—ADRA1A—central nervous system—Gilles de la Tourette syndrome	0.000706	0.018	CbGeAlD
Nefazodone—ADRA2A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000695	0.0115	CbGpPWpGaD
Nefazodone—Domperidone—DRD3—Gilles de la Tourette syndrome	0.000693	0.0772	CrCbGaD
Nefazodone—HTR2A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000691	0.0115	CbGpPWpGaD
Nefazodone—ADRA1B—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000687	0.0114	CbGpPWpGaD
Nefazodone—SLC6A4—brain—Gilles de la Tourette syndrome	0.000684	0.0174	CbGeAlD
Nefazodone—ADRA2A—midbrain—Gilles de la Tourette syndrome	0.000678	0.0173	CbGeAlD
Nefazodone—ADRA1A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000677	0.0112	CbGpPWpGaD
Nefazodone—ADRA2A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000675	0.0112	CbGpPWpGaD
Nefazodone—HTR1A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000672	0.0112	CbGpPWpGaD
Nefazodone—HTR2C—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000669	0.0111	CbGpPWpGaD
Nefazodone—HTR2A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000642	0.0107	CbGpPWpGaD
Nefazodone—ADRA1B—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00064	0.0106	CbGpPWpGaD
Nefazodone—Acetophenazine—DRD2—Gilles de la Tourette syndrome	0.000633	0.0705	CrCbGaD
Nefazodone—ADRA1A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000629	0.0104	CbGpPWpGaD
Nefazodone—ADRA2A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000629	0.0104	CbGpPWpGaD
Nefazodone—HTR2A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000624	0.0103	CbGpPWpGaD
Nefazodone—Aripiprazole—DRD4—Gilles de la Tourette syndrome	0.000621	0.0691	CrCbGaD
Nefazodone—ADRA1A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000611	0.0101	CbGpPWpGaD
Nefazodone—HTR1A—brain—Gilles de la Tourette syndrome	0.000608	0.0155	CbGeAlD
Nefazodone—SLC6A2—brain—Gilles de la Tourette syndrome	0.000603	0.0153	CbGeAlD
Nefazodone—ADRA2A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000584	0.00969	CbGpPWpGaD
Nefazodone—HTR2A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000581	0.00963	CbGpPWpGaD
Nefazodone—HTR2A—midbrain—Gilles de la Tourette syndrome	0.000576	0.0147	CbGeAlD
Nefazodone—ADRA1A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000569	0.00943	CbGpPWpGaD
Nefazodone—ADRA2A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000567	0.00941	CbGpPWpGaD
Nefazodone—HTR1A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00056	0.00929	CbGpPWpGaD
Nefazodone—ADRA1A—brain—Gilles de la Tourette syndrome	0.00056	0.0143	CbGeAlD
Nefazodone—HTR2C—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000557	0.00924	CbGpPWpGaD
Nefazodone—ADRA2A—nervous system—Gilles de la Tourette syndrome	0.000557	0.0142	CbGeAlD
Nefazodone—ADRA2A—central nervous system—Gilles de la Tourette syndrome	0.000536	0.0137	CbGeAlD
Nefazodone—Aripiprazole—DRD3—Gilles de la Tourette syndrome	0.000535	0.0596	CrCbGaD
Nefazodone—ADRA1B—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000534	0.00885	CbGpPWpGaD
Nefazodone—ADRA2A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000528	0.00876	CbGpPWpGaD
Nefazodone—Domperidone—DRD2—Gilles de la Tourette syndrome	0.00048	0.0534	CrCbGaD
Nefazodone—Prochlorperazine—DRD3—Gilles de la Tourette syndrome	0.000477	0.0531	CrCbGaD
Nefazodone—ADRA1A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000474	0.00786	CbGpPWpGaD
Nefazodone—HTR2A—nervous system—Gilles de la Tourette syndrome	0.000474	0.0121	CbGeAlD
Nefazodone—HTR1A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000471	0.00781	CbGpPWpGaD
Nefazodone—HTR2C—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000468	0.00777	CbGpPWpGaD
Nefazodone—HTR2A—central nervous system—Gilles de la Tourette syndrome	0.000456	0.0116	CbGeAlD
Nefazodone—ADRA1B—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000448	0.00744	CbGpPWpGaD
Nefazodone—ADRA2A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00044	0.0073	CbGpPWpGaD
Nefazodone—CYP3A4—nervous system—Gilles de la Tourette syndrome	0.000439	0.0112	CbGeAlD
Nefazodone—CYP2D6—nervous system—Gilles de la Tourette syndrome	0.000432	0.011	CbGeAlD
Nefazodone—Fluphenazine—DRD3—Gilles de la Tourette syndrome	0.000432	0.0481	CrCbGaD
Nefazodone—ADRA2A—brain—Gilles de la Tourette syndrome	0.000426	0.0109	CbGeAlD
Nefazodone—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.000424	0.00703	CbGpPWpGaD
Nefazodone—CYP3A4—central nervous system—Gilles de la Tourette syndrome	0.000422	0.0108	CbGeAlD
Nefazodone—CYP2D6—central nervous system—Gilles de la Tourette syndrome	0.000416	0.0106	CbGeAlD
Nefazodone—Zuclopenthixol—DRD2—Gilles de la Tourette syndrome	0.000401	0.0446	CrCbGaD
Nefazodone—ADRA1A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000398	0.00661	CbGpPWpGaD
Nefazodone—Quetiapine—DRD4—Gilles de la Tourette syndrome	0.000388	0.0432	CrCbGaD
Nefazodone—ABCB1—midbrain—Gilles de la Tourette syndrome	0.000378	0.00962	CbGeAlD
Nefazodone—Aripiprazole—DRD2—Gilles de la Tourette syndrome	0.000371	0.0413	CrCbGaD
Nefazodone—ADRA2A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00037	0.00614	CbGpPWpGaD
Nefazodone—HTR2A—brain—Gilles de la Tourette syndrome	0.000362	0.00923	CbGeAlD
Nefazodone—SLC6A4—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000356	0.0059	CbGpPWpGaD
Nefazodone—Thioproperazine—DRD2—Gilles de la Tourette syndrome	0.000351	0.0391	CrCbGaD
Nefazodone—HTR2A—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.000339	0.00563	CbGpPWpGaD
Nefazodone—Quetiapine—DRD3—Gilles de la Tourette syndrome	0.000335	0.0373	CrCbGaD
Nefazodone—Prochlorperazine—DRD2—Gilles de la Tourette syndrome	0.00033	0.0368	CrCbGaD
Nefazodone—CYP2D6—brain—Gilles de la Tourette syndrome	0.00033	0.0084	CbGeAlD
Nefazodone—HTR2A—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.000329	0.00546	CbGpPWpGaD
Nefazodone—ABCB1—nervous system—Gilles de la Tourette syndrome	0.00031	0.00791	CbGeAlD
Nefazodone—Zuclopenthixol—HTR2A—Gilles de la Tourette syndrome	0.00031	0.0345	CrCbGaD
Nefazodone—SLC6A2—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000306	0.00507	CbGpPWpGaD
Nefazodone—SLC6A4—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.000299	0.00496	CbGpPWpGaD
Nefazodone—ABCB1—central nervous system—Gilles de la Tourette syndrome	0.000299	0.00762	CbGeAlD
Nefazodone—Fluphenazine—DRD2—Gilles de la Tourette syndrome	0.000299	0.0333	CrCbGaD
Nefazodone—SLC6A4—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.00029	0.00482	CbGpPWpGaD
Nefazodone—Aripiprazole—HTR2A—Gilles de la Tourette syndrome	0.000286	0.0319	CrCbGaD
Nefazodone—Trazodone—HTR2A—Gilles de la Tourette syndrome	0.000285	0.0317	CrCbGaD
Nefazodone—Thioproperazine—HTR2A—Gilles de la Tourette syndrome	0.000271	0.0302	CrCbGaD
Nefazodone—SLC6A4—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.000271	0.00449	CbGpPWpGaD
Nefazodone—Trifluoperazine—DRD2—Gilles de la Tourette syndrome	0.000239	0.0266	CrCbGaD
Nefazodone—ABCB1—brain—Gilles de la Tourette syndrome	0.000237	0.00605	CbGeAlD
Nefazodone—Perphenazine—DRD2—Gilles de la Tourette syndrome	0.000236	0.0263	CrCbGaD
Nefazodone—SLC6A4—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.000232	0.00385	CbGpPWpGaD
Nefazodone—Quetiapine—DRD2—Gilles de la Tourette syndrome	0.000232	0.0258	CrCbGaD
Nefazodone—Fluphenazine—HTR2A—Gilles de la Tourette syndrome	0.000231	0.0257	CrCbGaD
Nefazodone—SLC6A2—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.000193	0.0032	CbGpPWpGaD
Nefazodone—Trifluoperazine—HTR2A—Gilles de la Tourette syndrome	0.000184	0.0205	CrCbGaD
Nefazodone—HTR1A—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.000184	0.00305	CbGpPWpGaD
Nefazodone—Perphenazine—HTR2A—Gilles de la Tourette syndrome	0.000182	0.0203	CrCbGaD
Nefazodone—Quetiapine—HTR2A—Gilles de la Tourette syndrome	0.000179	0.0199	CrCbGaD
Nefazodone—HTR1A—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.000179	0.00296	CbGpPWpGaD
Nefazodone—HTR1A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000171	0.00283	CbGpPWpGaD
Nefazodone—HTR2C—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00017	0.00282	CbGpPWpGaD
Nefazodone—HTR1A—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.000166	0.00276	CbGpPWpGaD
Nefazodone—HTR1A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000166	0.00275	CbGpPWpGaD
Nefazodone—HTR2C—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000165	0.00273	CbGpPWpGaD
Nefazodone—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000163	0.0027	CbGpPWpGaD
Nefazodone—HTR1A—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.000162	0.00268	CbGpPWpGaD
Nefazodone—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000158	0.00262	CbGpPWpGaD
Nefazodone—HTR1A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000154	0.00256	CbGpPWpGaD
Nefazodone—HTR2C—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000154	0.00255	CbGpPWpGaD
Nefazodone—HTR2A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000147	0.00245	CbGpPWpGaD
Nefazodone—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000147	0.00244	CbGpPWpGaD
Nefazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000146	0.00243	CbGpPWpGaD
Nefazodone—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000145	0.00241	CbGpPWpGaD
Nefazodone—ADRA2A—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.000145	0.0024	CbGpPWpGaD
Nefazodone—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000144	0.00239	CbGpPWpGaD
Nefazodone—HTR2A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000143	0.00237	CbGpPWpGaD
Nefazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000142	0.00235	CbGpPWpGaD
Nefazodone—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000141	0.00234	CbGpPWpGaD
Nefazodone—ADRA2A—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00014	0.00233	CbGpPWpGaD
Nefazodone—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00014	0.00232	CbGpPWpGaD
Nefazodone—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000139	0.00231	CbGpPWpGaD
Nefazodone—HTR2C—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000139	0.00231	CbGpPWpGaD
Nefazodone—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000135	0.00224	CbGpPWpGaD
Nefazodone—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000134	0.00222	CbGpPWpGaD
Nefazodone—HTR2A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000133	0.00221	CbGpPWpGaD
Nefazodone—ADRA1B—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000133	0.00221	CbGpPWpGaD
Nefazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000132	0.00219	CbGpPWpGaD
Nefazodone—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000132	0.00218	CbGpPWpGaD
Nefazodone—ADRA2A—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.000131	0.00217	CbGpPWpGaD
Nefazodone—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000131	0.00217	CbGpPWpGaD
Nefazodone—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00013	0.00216	CbGpPWpGaD
Nefazodone—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000126	0.0021	CbGpPWpGaD
Nefazodone—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000126	0.00209	CbGpPWpGaD
Nefazodone—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000124	0.00206	CbGpPWpGaD
Nefazodone—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000124	0.00205	CbGpPWpGaD
Nefazodone—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000123	0.00203	CbGpPWpGaD
Nefazodone—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000121	0.00201	CbGpPWpGaD
Nefazodone—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00012	0.00199	CbGpPWpGaD
Nefazodone—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000119	0.00198	CbGpPWpGaD
Nefazodone—ADRA1A—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000118	0.00196	CbGpPWpGaD
Nefazodone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000115	0.00191	CbGpPWpGaD
Nefazodone—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000114	0.00189	CbGpPWpGaD
Nefazodone—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000112	0.00186	CbGpPWpGaD
Nefazodone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000112	0.00185	CbGpPWpGaD
Nefazodone—HTR1A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000111	0.00185	CbGpPWpGaD
Nefazodone—HTR2C—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000111	0.00184	CbGpPWpGaD
Nefazodone—HTR1A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000108	0.00179	CbGpPWpGaD
Nefazodone—HTR1A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000108	0.00179	CbGpPWpGaD
Nefazodone—HTR2C—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000108	0.00178	CbGpPWpGaD
Nefazodone—HTR2C—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000108	0.00178	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—HDC—Gilles de la Tourette syndrome	0.000106	0.00176	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000106	0.00176	CbGpPWpGaD
Nefazodone—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000106	0.00175	CbGpPWpGaD
Nefazodone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000104	0.00172	CbGpPWpGaD
Nefazodone—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000103	0.00171	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000103	0.00171	CbGpPWpGaD
Nefazodone—HTR1A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000101	0.00167	CbGpPWpGaD
Nefazodone—HTR2C—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.0001	0.00166	CbGpPWpGaD
Nefazodone—SLC6A2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	9.79e-05	0.00162	CbGpPWpGaD
Nefazodone—HTR2A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	9.62e-05	0.0016	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	9.59e-05	0.00159	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	9.42e-05	0.00156	CbGpPWpGaD
Nefazodone—HTR2A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	9.34e-05	0.00155	CbGpPWpGaD
Nefazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	9.26e-05	0.00154	CbGpPWpGaD
Nefazodone—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	9.21e-05	0.00153	CbGpPWpGaD
Nefazodone—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	9.15e-05	0.00152	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	9.14e-05	0.00152	CbGpPWpGaD
Nefazodone—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	8.82e-05	0.00146	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	8.75e-05	0.00145	CbGpPWpGaD
Nefazodone—HTR2A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	8.7e-05	0.00144	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	8.52e-05	0.00141	CbGpPWpGaD
Nefazodone—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	8.5e-05	0.00141	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	8.5e-05	0.00141	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—HDC—Gilles de la Tourette syndrome	8.39e-05	0.00139	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	7.92e-05	0.00131	CbGpPWpGaD
Nefazodone—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	7.84e-05	0.0013	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—HDC—Gilles de la Tourette syndrome	7.69e-05	0.00128	CbGpPWpGaD
Nefazodone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	7.28e-05	0.00121	CbGpPWpGaD
Nefazodone—HTR1A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	7.05e-05	0.00117	CbGpPWpGaD
Nefazodone—HTR2C—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	7.02e-05	0.00116	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	6.72e-05	0.00111	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	6.29e-05	0.00104	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	6.26e-05	0.00104	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	6.11e-05	0.00101	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	6.08e-05	0.00101	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	5.99e-05	0.000994	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	5.97e-05	0.00099	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	5.82e-05	0.000965	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—HDC—Gilles de la Tourette syndrome	5.8e-05	0.000962	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	5.71e-05	0.000948	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	5.69e-05	0.000944	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	5.69e-05	0.000943	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	5.66e-05	0.000939	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	5.55e-05	0.00092	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	5.54e-05	0.000919	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	5.52e-05	0.000915	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—HDC—Gilles de la Tourette syndrome	5.47e-05	0.000907	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	5.44e-05	0.000903	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	5.44e-05	0.000902	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	5.42e-05	0.000899	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	5.32e-05	0.000883	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	5.28e-05	0.000876	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	5.28e-05	0.000875	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	5.17e-05	0.000857	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	5.17e-05	0.000857	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	5.14e-05	0.000853	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	4.95e-05	0.00082	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	4.94e-05	0.000819	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	4.92e-05	0.000816	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	4.92e-05	0.000815	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	4.83e-05	0.000802	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	4.81e-05	0.000798	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	4.8e-05	0.000796	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	4.79e-05	0.000795	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	4.69e-05	0.000778	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	4.49e-05	0.000745	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	4.47e-05	0.000742	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	4.46e-05	0.00074	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	4.37e-05	0.000725	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	4.36e-05	0.000723	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	4.31e-05	0.000715	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	4.06e-05	0.000674	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	3.99e-05	0.000661	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	3.97e-05	0.000658	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	3.8e-05	0.00063	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.62e-05	0.0006	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.6e-05	0.000597	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—HDC—Gilles de la Tourette syndrome	3.58e-05	0.000593	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.45e-05	0.000572	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.38e-05	0.00056	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	3.37e-05	0.000559	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.36e-05	0.000557	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.28e-05	0.000544	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.26e-05	0.000541	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.21e-05	0.000533	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	3.13e-05	0.00052	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.12e-05	0.000518	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.06e-05	0.000508	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.05e-05	0.000506	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.04e-05	0.000504	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	2.92e-05	0.000484	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	2.91e-05	0.000482	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	2.86e-05	0.000474	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	2.84e-05	0.000472	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	2.83e-05	0.00047	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	2.77e-05	0.00046	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	2.65e-05	0.00044	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	2.64e-05	0.000437	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	2.58e-05	0.000428	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	2.58e-05	0.000427	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	2.4e-05	0.000398	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.14e-05	0.000355	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.13e-05	0.000353	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.04e-05	0.000338	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	1.81e-05	0.0003	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	1.68e-05	0.000279	CbGpPWpGaD
